SOURCE: PetVivo Holdings, Inc.
EDEN PRAIRIE, MN--(Marketwired - May 21, 2014) - PetVivo Holdings, Inc. (OTCQB: PETV), an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics announced that CEO Mr. John Lai provided a comprehensive, in-depth interview to CEOCFO Magazine.
In the interview, Mr. Lai discusses how PetVivo is leveraging the accelerated timeline to revenues for veterinary medical devices that is facilitated by the investments already expended in the development of medical devices and biomaterials for human therapies. These devices, which often have already demonstrated safety and efficacy in animals, can be redirected into the veterinary therapeutics marketplace in a capital and time efficient way.
Mr. Lai provided overview of Kush™ a patented medical device for the treatment of animal lameness that the company has licensed and scheduled for commercial launch in Q4 2014. The Kush device is composed of protein matrix particles that are injected into the joint's synovial fluid to protect the joint by providing a cushion where the joint's natural cushioning cartilage is missing. Mr. Lai noted,"We believe the Kush particles substantially reduce joint inflammation and allows joint repair. In our animal studies, we observed much greater mobility soon after delivering this treatment. We have seen dogs eagerly willing to run, verses before injection where you would see them unwilling to move around much."
The Kush device is the first of a strong product pipeline of products being prepared by PetVivo. The company has been working with Dr. David Masters, CEO, inventor and founder of Gel-Del Technologies in St. Paul Minnesota, to bring veterinary device products to market under a license agreement, including Kush as the next great thing. Mr. Lai commented, "We actually have a pretty good idea of our product pipeline in that we are planning to focus on devices rather than pharmaceuticals so that we can bring products to market faster without a formal FDA-approval process and provide veterinarians better products to treat their patients."
To read this detailed, comprehensive CEOCFO Magazine interview, please access directly by clicking on the link below:
About PetVivo, Inc:
PetVivo, Inc. is a wholly owned subsidiary of PetVivo Holdings, Inc. (OTCQB: PETV) based in Minneapolis, Minnesota. PetVivo is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and other therapeutics for pets.
PetVivo, Inc. believes that it can leverage the investments in the human bio-materials and medical device industries to commercialize therapeutics to pets in a capital and time efficient way. PetVivo's strategy is to in-license proprietary products from human medical device companies specifically for use in pets. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
The fore-going material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.